drugset / Trial / NCT01898520
A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A study to assess the effects of Sativex treatment on spasticity in a population of children and adolescents aged from 8 to 18 years with cerebral palsy or traumatic central nervous system injury. Efficacy (ability to improve symptoms), safety and tolerability will be monitored.
Timeline
- Start
- 2013-12
- Primary completion
- 2016-09
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nabiximols | Other / unclassified | 2.5 mg | Oral |
| Comparator | Nabiximols | Other / unclassified | 2.7 mg | Oral |